<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913703</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00071271</org_study_id>
    <secondary_id>R01DK097550</secondary_id>
    <nct_id>NCT02913703</nct_id>
  </id_info>
  <brief_title>Preprandial Ghrelin Effect</brief_title>
  <official_title>Effect of Preprandial Ghrelin on Postprandial Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jenny Tong, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Significance: The peptide hormone ghrelin drives hunger and feeding behavior,
      making it a focus of obesity research. Released mainly by the stomach and proximal small
      intestine, ghrelin peaks prior to meals, potentially priming the gut for anticipated
      nutrients. After eating, ghrelin abruptly declines, with levels varying 2- to 3-fold between
      the fasted and fed states. Interestingly, in obesity and type 2 diabetes (T2D), this pattern
      is disrupted. Individuals with these disorders have chronically suppressed ghrelin levels and
      little variation before and after meals.

      Although ghrelin's preprandial rise and postprandial fall is a well-established phenomenon,
      its role in regulating glucose metabolism is unclear. In mice, increasing preprandial ghrelin
      levels improves glucose tolerance through enhanced glucagon-like peptide-1 (GLP-1) secretion.
      Ghrelin also stimulates GLP-1 secretion from mouse and human intestinal L-cells in vitro.
      These findings suggest enhanced postprandial GLP-1 as a novel role for the preprandial
      ghrelin surge. A ghrelin-incretin enteroendocrine axis could also explain the poor
      postprandial GLP-1 secretion and glucose tolerance in subjects with T2D, given their
      preprandial hypoghrelinemia.

      The investigators' preliminary data demonstrate that in humans, increasing circulating
      ghrelin to a supraphysiologic range worsened glucose tolerance, despite increased GLP-1
      secretion. The discrepancy between these findings and the ones from rodents could be due to
      difference in study design and/or species. For example, the investigators' study used a
      continuous ghrelin infusion, which resulted in elevated levels of ghrelin pre- and
      postprandially. Elevated postprandial ghrelin likely mitigated the positive effects of
      increased GLP-1 secretion by raising levels of glucagon and other counter-regulatory
      hormones.

      This study seeks to delineate the interactions between ghrelin and GLP-1 in the regulation of
      glucose tolerance, beta-cell function, and insulin sensitivity. The investigators hypothesize
      that increased preprandial ghrelin will enhance GLP-1 secretion and consequently improve
      glucose tolerance in healthy subjects and those with T2D. Confirmation of these hypotheses
      would advance the investigators understanding of the control of glucose homeostasis and have
      important clinical and therapeutic implications. Modulating ghrelin levels may provide a
      novel therapeutic strategy to improve glucose tolerance in individuals with T2D, which
      affects an estimated 350 million people worldwide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of preprandial ghrelin on glucose tolerance</measure>
    <time_frame>Approximately 4-8 weeks</time_frame>
    <description>Primary Outcome: Glucose area under the curve during 60-minute Meal Tolerance test in healthy subjects and in Type 2 diabetic subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of preprandial ghrelin on GLP-1 secretion</measure>
    <time_frame>Approx 4-8 weeks</time_frame>
    <description>Secondary Outcome: Effect of preprandial ghrelin on GLP-1 area under the curve during a mixed meal in healthy subjects and in Type 2 diabetic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of preprandial ghrelin on insulin secretion</measure>
    <time_frame>Approx 4-8 weeks</time_frame>
    <description>Secondary Outcome: Effect of preprandial ghrelin on insulin and c-peptide area under the curve during a mixed meal in healthy subjects and in Type 2 diabetic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of preprandial ghrelin on beta cell function</measure>
    <time_frame>Approx 4-8 weeks</time_frame>
    <description>Secondary Outcome: Effect of preprandial ghrelin on beta cell function (as measured by Disposition Index = [ (Area under the insulin curve / Area under the glucose curve) X Matsuda Index] during a 60-minute Meal Tolerance test in healthy subjects and in Type 2 diabetic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of preprandial ghrelin on insulin sensitivity (as measured by Matsuda index)</measure>
    <time_frame>Approx 4-8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy subjects - Preprandial AG (Acyl Ghrelin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects - Preprandial saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects - Prandial AG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects - Preprandial &amp; prandial AG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic subjects - Preprandial AG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic subjects - Preprandial Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin</intervention_name>
    <description>Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.</description>
    <arm_group_label>Healthy subjects - Preprandial AG (Acyl Ghrelin)</arm_group_label>
    <arm_group_label>Healthy subjects - Prandial AG</arm_group_label>
    <arm_group_label>Healthy subjects - Preprandial &amp; prandial AG</arm_group_label>
    <arm_group_label>Diabetic subjects - Preprandial AG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.</description>
    <arm_group_label>Healthy subjects - Preprandial saline</arm_group_label>
    <arm_group_label>Diabetic subjects - Preprandial Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        T2DM study subjects must meet the following inclusion criteria:

          -  established T2DM with good to moderate glycemic control (HbA1c â‰¤ 8.5%)

          -  Diabetes treated with oral medications or lifestyle management

          -  BMI 25.0 - 45.0 kg/m2

        Healthy control subjects must meet the following inclusion criteria:

          -  Fasting glucose &lt;100 mg/dL, as measured at screening visit

          -  HbA1c &lt; 5.7%, as measured at screening visit

          -  BMI 18.0 - 29.9 kg/m2

          -  No diagnosis of diabetes mellitus (including gestational diabetes)

          -  Age between 18 - 40 years

        Exclusion Criteria:

        All subjects will be excluded for the following reasons:

          -  Active infections

          -  History of malignant or inflammatory conditions, such as rheumatoid arthritis and
             inflammatory bowel disease

          -  History of myocardial infarction or congestive heart failure

          -  History or active liver or renal disease (AST or ALT &gt;2x upper limits of normal,
             calculated glomerular filtration rate [eGFR] &lt;60 at screening)

          -  Anemia defined as hematocrit &lt;34% at screening visit

          -  Uncontrolled hypertension

          -  History of pituitary or adrenal disorders or neuroendocrine tumor

          -  History of anorexia nervosa or previous gastrointestinal surgery

          -  Malabsorptive GI disease, such as celiac disease

          -  Pregnancy or lactation

          -  Use of medications that alter glucose metabolism or GI function (glucocorticoids,
             psychotropics, niacin, narcotic, metoclopramide)

          -  Use of insulin or GLP-1 based therapy (i.e. DPP-4 inhibitors, GLP-1 receptor agonists)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Tong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna L Johnson, MS</last_name>
    <phone>919-660-6766</phone>
    <email>johanna.johnson@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cris A Slentz, PhD</last_name>
    <phone>919-660-6743</phone>
    <email>cris.slentz@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Center For Living</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna L Johnson, MS</last_name>
      <phone>919-660-6766</phone>
      <email>johanna.johnson@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cris A Slentz, PhD</last_name>
      <phone>919-660-6743</phone>
      <email>cris.slentz@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jenny Tong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jenny Tong, MD, MPH</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ghrelin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

